Prognostic value of flow cytometry in myelodysplastic neoplasms (MDS): Composition of a FCM‐prognostic score (FCM‐PS) for overall survival
Aida Santaolalla(King's College London), Shahram Kordasti(Marche Polytechnic University), Theresia M. Westers(Vrije Universiteit Amsterdam), Shirin Jamshidi(King's College London), Farzin Farzaneh, A. S. Kubasch(University Hospital Leipzig), Susann Winter(University Hospital Carl Gustav Carus), Katja Sockel(Innsbruck Medical University), Antonella Poloni(Marche Polytechnic University), Rosa Andres Ejarque(Guy's Hospital), M Van Hemelrijck(King's College London), Uwe Platzbecker, Arjan A. van de Loosdrecht(Amsterdam University Medical Centers), Martin Bornhäuser(University Hospital Carl Gustav Carus), Uta Oelschlaegel(University Hospital Carl Gustav Carus)
Cited by 0
Related Papers
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
|Leukemia|2011|398
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
|The Lancet|2020|366
Bone marrow adipose tissue is a unique adipose subtype with distinct roles in glucose homeostasis
|Nature Communications|2020|197